Cary Claiborne - CEO, Adial Pharmaceuticals - Treatment And Prevention Of Addictions

Progress, Potential, and Possibilities

Send us a text

Cary Claiborne is CEO of Adial Pharmaceuticals ( https://www.adial.com/ ), a clinical-stage biopharma company focused on developing therapies for the treatment of addiction and related diseases, specifically Alcohol Use Disorder (AUD). In the U.S. alone, an estimated 35 million people suffer from AUD, resulting in significant health, social and financial costs. Current treatment options present significant barriers to patient adoption, including abstinence and side effects, which can lead to social stigmatization.
Mr. Claiborne has over three decades of experience in leadership roles with clinical and commercial stage, publicly traded biopharmaceutical companies.
Most recently, Mr. Claiborne served as Chief Financial Officer and director of Indivior PLC, a publicly traded specialty pharmaceutical company developing medicines to treat addiction and serious mental illnesses. He led Indivior’s spin-off from its then parent company, Reckitt Benckiser, to become an independent, publicly traded company.
Prior to joining Indivior, Mr. Claiborne served as the CFO of Sucampo Pharmaceuticals, Inc., a global biopharmaceutical company, which was later sold to Mallinckrodt.
Before joining Sucampo, Mr. Claiborne served as CFO and Corporate Secretary of Osiris Therapeutics, Inc. during the company’s initial public offering.
Mr. Claiborne currently sits on the boards of NeuroSense Therapeutics, a clinical-stage drug development company that is advancing a treatment for people living with amyotrophic lateral sclerosis, and CytRx Corporation, a biopharmaceutical company focused on discovering and developing new cancer therapeutics.
Mr. Claiborne graduated from Rutgers University with a B.A. in Business Administration and earned his M.B.A from Villanova University and was a National Association of Corporate Directors (NACD) Governance Fellow.

Support the show